Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Eiger BioPharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5101, 5110(b), IM-5101-1
Exact text from the filing
April 2, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Delisting Notice also advises the Company of its right to appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company does not intend to pursue an appeal.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jeffrey S. Glenn resigned as Member of the Board of Directors at Eiger BioPharmaceuticals, Inc..
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
On April 1, 2024, Jeffrey S. Glenn notified the Company of his resignation as a member of the Company’s Board of Directors, to be effective April 1, 2024.
View on SEC.gov